Nucleotide Protein -3 in Epileptic Children
Biochemical Role of Nucleotide Protein -3 That Activate the Interleukin-1B in Epileptic Children
1 other identifier
observational
80
0 countries
N/A
Brief Summary
Epilepsy is one of common serious neurological malfunction, characterized by recurrent unprovoked seizures. It always accompanied with multitude of complications as cognitive, behavioral, and psychiatric disorders. Experimental studies and clinical evidence obtained in animal models of epilepsy and human brain specimen from various drug-resistant forms of epilepsy show the activation of the innate and adaptive immunity mechanisms and the induction of the associated inflammatory processes in the epileptogenic foci.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2020
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 3, 2020
CompletedFirst Posted
Study publicly available on registry
January 7, 2020
CompletedStudy Start
First participant enrolled
February 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedJanuary 9, 2020
January 1, 2020
9 months
January 3, 2020
January 6, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The mean difference of nucleotide protein -3 inflammatory marker expression in epileptic children and controls
better understanding the role of inflammation in pathogenesis of epilepsy in children
Baseline
Study Arms (2)
epileptic children
fifty patient with epilepsy
Healthy controls
thirty healthy control
Interventions
Expression of nucleotide protein -3 will be measured in serum by ELISA
Eligibility Criteria
Epileptic children
You may qualify if:
- Epileptic children in Assiut university hospital, pediatric department, neurology unit.
You may not qualify if:
- Children with other chronic disease such as liver, kidney or heart disease
- patient who have apparent infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (3)
He Q, Jiang L, Man S, Wu L, Hu Y, Chen W. Curcumin Reduces Neuronal Loss and Inhibits the NLRP3 Inflammasome Activation in an Epileptic Rat Model. Curr Neurovasc Res. 2018;15(3):186-192. doi: 10.2174/1567202615666180731100224.
PMID: 30062967BACKGROUNDFarghaly WM, Abd Elhamed MA, Hassan EM, Soliman WT, Yhia MA, Hamdy NA. Prevalence of childhood and adolescence epilepsy in Upper Egypt (desert areas). Egypt J Neurol Psychiatr Neurosurg. 2018;54(1):34. doi: 10.1186/s41983-018-0032-0. Epub 2018 Nov 9.
PMID: 30532513BACKGROUNDXu D, Miller SD, Koh S. Immune mechanisms in epileptogenesis. Front Cell Neurosci. 2013 Nov 8;7:195. doi: 10.3389/fncel.2013.00195. eCollection 2013.
PMID: 24265605BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 3, 2020
First Posted
January 7, 2020
Study Start
February 1, 2020
Primary Completion
November 1, 2020
Study Completion
December 1, 2020
Last Updated
January 9, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will not share